Biostax

Biostax FCF/Debt

The Free Cash Flow to Debt Ratio of Biostax (BTAX) as of Oct 16, 2026 is -28.64 %. In the previous year, Free Cash Flow to Debt Ratio was -53.32 % — a change of -46.29% (higher).

FCF/Debt

-28.64 %

YoY

-46.29%

Last updated:

Free Cash Flow to Debt Ratio of Biostax is 2023 -28.64 % . Free Cash Flow to Debt Ratio of Biostax was 2022 -53.32 % . It decreases by -46.29% higher compared to the previous year.

The Biostax FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2016
-67.25 USD
Jan 1, 2017
-42.63 USD
Jan 1, 2018
-26.44 USD
Jan 1, 2019
-0.02 USD
Jan 1, 2020
-5.69 USD
Jan 1, 2021
-5.85 USD
Jan 1, 2022
-53.32 USD
Jan 1, 2023
-28.64 USD
The Biostax FCF/Debt history
YEARFCF/DebtYoY
-28.64 %-46.29%
-53.32 %+811.62%
-5.85 %+2.85%
-5.69 %+34,938.91%
-0.02 %-99.94%
-26.44 %-37.98%
-42.63 %-36.61%
-67.25 %-33.67%
-101.38 %-86.66%
-759.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biostax Stock analysis

What does Biostax do? Biostax Corp, trading under the ticker BTAX with ISIN US45252A3059, is a U.S.-based biotechnology company headquartered in Winter Park. The company went public via an IPO on July 16, 2001. Biostax Corp operates within the Health Care sector, specifically in the Biotechnology industry. The company's website is https://www.biostaxcorp.com/. Biostax Corp has established partnerships in the fields of autoimmunity and immune restoration, focusing on solutions for conditions including autoimmunity, chronic inflammation, infection, and cancer. The company's subsidiary, BiostaxRx, is dedicated to the treatment of inflammaging disease. Biostax Corp's product portfolio includes Londonal, JKB-122, and Low Dose Naltrexone. Londonal is described as a once-a-day immune system regulator for managing HIV/AIDS. JKB-122 is a therapy targeting Autoimmune Hepatitis (AIH), Nonalcoholic fatty liver disease (NAFLD), and Nonalcoholic steatohepatitis (NASH), with properties that are anti-fibrotic, immune modulating, and/or anti-inflammatory. The company's operations and product descriptions are based on the information provided in the source description, which is treated as untrusted. No additional details regarding founding year, key personnel, acquisitions, or specific financial figures are included in the provided facts. Biostax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostax stock

Free Cash Flow to Debt Ratio of Biostax is -28.64 % in 2023.

Free Cash Flow to Debt Ratio of Biostax changed from -53.32 % to -28.64 %, representing a -46.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Biostax since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Biostax with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Biostax

All Key Metrics — Biostax